AbCellera Biologics Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ABCL Nasdaq 2830 www.abcellera.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AbCellera Biologics Inc.

AbCellera Biologics Inc. (ABCL): A Bull Case Theory - Feb 2nd, 2026 5:49 pm
AbCellera’s ABCL635 Phase 2 Start Highlights Menopause Focus And Valuation Gap - Jan 30th, 2026 10:09 pm
AbCellera Biologics (ABCL) Valuation Check After Mixed Long Term Shareholder Returns - Jan 30th, 2026 6:13 am
Reassessing AbCellera Biologics (ABCL) After A Sharp 16.8% Weekly Share Price Drop - Jan 29th, 2026 11:17 pm
What Does Wall Street Think About AbCellera Biologics Inc. (ABCL)? - Jan 29th, 2026 11:49 am
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026 - Jan 22nd, 2026 2:05 pm
AbCellera Biologics Pivots to Internal Pipeline at JPMorgan, Teases Key Milestones for 2026 - Jan 14th, 2026 6:07 pm
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause - Jan 12th, 2026 7:00 am
3 Promising Penny Stocks With Market Caps Under $2B - Jan 7th, 2026 5:05 am
We're Not Worried About AbCellera Biologics' (NASDAQ:ABCL) Cash Burn - Dec 25th, 2025 6:05 am
Sector Update: Health Care Stocks Rise Late Afternoon - Dec 18th, 2025 1:55 pm
AbCellera and Bruker Reach Global Settlement of Patent Litigation - Dec 18th, 2025 7:00 am
AbCellera Biologics Inc (ABCL) Down 23% Since Q3 2025 Results - Dec 4th, 2025 8:09 pm
SunCar Technology Group And 2 Other Penny Stocks To Consider - Nov 28th, 2025 5:04 am
Insider Spends US$178k Buying More Shares In AbCellera Biologics - Nov 28th, 2025 3:13 am
AbCellera Biologics Inc. (ABCL) is a Buy at Stifel Nicolaus despite Wider Q3 Net Loss - Nov 25th, 2025 6:16 am
Why Wall Street Maintains Buy Stance on AbCellera Biologics Inc. (ABCL) Amid Business Model Evolution? - Nov 18th, 2025 4:17 am
AbCellera Appoints Dr. Stephen Quake to its Board of Directors - Nov 10th, 2025 7:00 am
Assessing AbCellera Biologics (ABCL) Valuation Following Phase 1 Trial Progress and Clinical Milestones - Nov 9th, 2025 2:20 am
AbCellera Biologics Inc (ABCL) Q3 2025 Earnings Call Highlights: Transition to Clinical-Stage ... - Nov 6th, 2025 10:12 pm